NASDAQ:KURA Kura Oncology Q3 2026 Earnings Report $10.53 -0.09 (-0.85%) Closing price 10/6/2026 04:00 PM EasternExtended Trading$10.42 -0.10 (-1.00%) As of 07:30 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Kura Oncology EPS ResultsActual EPSN/AConsensus EPS -$0.81Beat/MissN/AOne Year Ago EPSN/AKura Oncology Revenue ResultsActual RevenueN/AExpected Revenue$23.81 millionBeat/MissN/AYoY Revenue GrowthN/AKura Oncology Announcement DetailsQuarterQ3 2026Date11/3/2026TimeAfter Market ClosesConference Call DateTuesday, November 3, 2026Conference Call Time8:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Kura Oncology Earnings HeadlinesCaspian Therapeutics and Kura Oncology to Host Investor Webcast on Caspian Formation and KO-7246 Data from EASD Meeting9 minutes ago | quiverquant.comQCaspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian's Launch and KO-7246 Preclinical Data in Diabetes25 minutes ago | globenewswire.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.October 7 at 1:00 AM | Investors Alley (Ad)JPMorgan Chase & Co. Initiates Coverage on Kura Oncology (NASDAQ:KURA)October 3, 2026 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Kura Oncology (KURA) and AbbVie (ABBV)October 2, 2026 | theglobeandmail.comKura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 2, 2026 | globenewswire.comSee More Kura Oncology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Kura Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kura Oncology and other key companies, straight to your email. Email Address About Kura OncologyKura Oncology (NASDAQ:KURA) is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company uses molecular and genomic insights to identify therapies designed to target specific biological drivers of tumor growth. Kura’s lead program is ziftomenib, an oral menin inhibitor developed for genetically defined forms of acute myeloid leukemia, including disease associated with NPM1 mutations and KMT2A rearrangements. The company has also evaluated additional targeted oncology candidates, including therapies directed at the RAF-MEK-ERK signaling pathway. Founded in 2014 and headquartered in San Diego, California, Kura has conducted clinical development activities through research collaborations and studies involving patients and institutions in the United States and other regions. Its programs are intended to address cancers with significant unmet medical needs by matching targeted treatments to specific molecular characteristics.View Kura Oncology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Lamb Weston’s Turnaround Is Starting to Look RealAI Chip Demand Gives Linde a New Growth CatalystAllient’s Data Center and Defense Momentum Is Raising the StakesInvenTrust’s Sell-Off Opens a Potential Entry PointCuraleaf’s Higher Aurora Bid Raises the Stakes in Cannabis Consolidation3 Low-Rated Stocks Analysts May Be Underestimating Ahead of Q3 EarningsNVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can Run Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
